Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis
A legfontosabb adatok
- Ki végzi
- BioNanoSim Ltd.
- Hol
- Izrael7 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1/2. fázis
- Résztvevők
- 18 fő vett részt
- Kezdés
- 2024. márc. 7.
- Befejezés
- 2025. márc. 25.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Oftac: 0.05% tacrolimus ophthalmic emulsion
- A regiszteradat frissítve
- 2026. október 13.
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Able and willing to provide written informed consent
- Able and willing to follow all study instructions, restrictions and attend study visits
- Male and female patients 18 to 70 years of age
- Patient has one of the following:; 4.1 A history of unilateral or bilateral ongoing (>/= 2 months) non-infectious anterior uveitis with chronic cellular infiltrate of +1 to +2 cells that has responded to steroids 4.2 A well-defined history of at least one episodes of acute anterior uveitis that responded to topical steroids and is currently with +1 to +2 cells, including patients that are on systemic stable therapy (oral immunosuppressive or injectable anti-TNF alpha inhibitors)
- BCVA equal or better than 0.3 Log MAR in the non-investigated eye
Ki nem vehet részt
- Have known contraindications or a sensitivity to any of the study drugs or excipients
- Plan to have any form of eye surgery within the study period or less than 3 months prior to screening
- Have IOP < 6 millimeters of mercury (mmHg) or > 20 mmHg while being treated with more than two anti-glaucoma medications in the investigated eye on maximal antiglaucoma therapy
- Patient is using a cytochrome P450-3A4 inhibitor inducer (such as but not limited to rifampin, carbamazepine, St. John's Wort, etc)
- Have an active ocular infection (bacterial, viral, or fungal)
- Have active non-uveitic ocular inflammation (e.g., severe blepharitis, any active allergic conjunctivitis, peripheral ulcerative keratitis or scleritis) in either eye
- Have a known history or diagnosis of ocular herpes-simplex infection
- Have a history of old posterior uveitis, or scars or intermediate uveitis that was active during the last six months
- Have clinically significant abnormal ophthalmic findings (e.g. central corneal scar, advanced guttata) or a known history of a clinically significant eye disease in either eye that may interfere with the study examinations and/or put the patient in any risk according to the Investigator's judgment
- Have a condition or a situation that in the Investigator's opinion may put the subject at increased risk, confound study data or interfere significantly with the subject's study participation, including but not limited to unstable cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic or psychiatric disease
- Patient is using cyclosporine or tacrolimus for any condition and via any route of administration
- Be a female of childbearing potential who is currently pregnant, nursing, or planning to become pregnant or nurse during the study
- Have active posterior-uveitis and/or active intermediate uveitis or any other form of active uveitis aside from anterior uveitis
- Have chronic Anterior Chamber (AC) flare >/= +3
- Have high myopia (above 9 diopters) or astigmatism (above 4 diopters) in the study eye
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
1. Are adverse events observed during the treatment period and if so, what are their severity? 2. What is the change in Best Corrected Visual Acuity (BCVA) test using the Early Treatment Diabetic Retinopathy Study (ETDRS) acuity chart from baseline to Day 29? 3. What is the change in Intraocular Pressure (IOP) from baseline to Day 29?
The expected study duration for each patient will be up to 6 weeks including up to 1 week for screening, a 4-week treatment period and a 1-week safety follow-up period. Patients will be administered Oftac 0.05% eye drops four (4) times every day, for up to six weeks.
A vizsgálat csoportja
- Oftac: 0.05% tacrolimus ophthalmic emulsionA vizsgált kezelés
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter, Open Label Phase-1/2a Study of Oftac Eye Drops in Active Non-Infectious Anterior Uveitis Patients
- A regiszteradat frissítve
- 2026. október 13.